• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Pembrolizumab+chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma].

作者信息

Duval Martin, Zaanan Aziz

机构信息

Service d'oncologie médicale, institut Curie, hôpital René-Huguenin-Saint-Cloud, 35, rue Dailly, 92210 Saint-Cloud, France.

Département d'oncologie digestive, hôpital européen Georges-Pompidou (HEGP), Assistance publique-Hôpitaux de Paris (AP-HP), université Paris Cité, institut du cancer parisien CARPEM, 20, rue Leblanc 75015 Paris, France.

出版信息

Bull Cancer. 2024 May;111(5):431-432. doi: 10.1016/j.bulcan.2024.01.004. Epub 2024 Mar 7.

DOI:10.1016/j.bulcan.2024.01.004
PMID:38458924
Abstract
摘要

相似文献

1
[Pembrolizumab+chemotherapy as first-line treatment in patients with HER2 negative advanced oesogastric adenocarcinoma].帕博利珠单抗联合化疗作为HER2阴性晚期食管胃腺癌患者的一线治疗方案
Bull Cancer. 2024 May;111(5):431-432. doi: 10.1016/j.bulcan.2024.01.004. Epub 2024 Mar 7.
2
[New EMA drug approval: Nivolumab in association with chemotherapy as first line treatment for HER2-negative esophageal adenocarcinoma with PD-L1 expression (CPS≥5)].[欧洲药品管理局（EMA）新批准的药物：纳武利尤单抗联合化疗作为一线治疗用于治疗PD-L1表达（综合阳性评分[CPS]≥5）的HER2阴性食管腺癌]
Bull Cancer. 2022 Feb;109(2):109-110. doi: 10.1016/j.bulcan.2021.11.012. Epub 2022 Jan 4.
3
Pembrolizumab in HER2-Positive Gastric Cancer.帕博利珠单抗治疗HER2阳性胃癌
N Engl J Med. 2024 Oct 10;391(14):1360-1362. doi: 10.1056/NEJMc2408121. Epub 2024 Sep 14.
4
[New drug approval: Pembrolizumab in association with chemotherapy as first line treatment for advanced/metastatic oesophageal carcinomas or HERnegative gastroesophageal adenocarcinoma, expressing PD-L1 with a CPS≥10].新药批准：帕博利珠单抗联合化疗作为晚期/转移性食管癌或HER阴性胃食管腺癌的一线治疗，其PD-L1表达且CPS≥10
Bull Cancer. 2022 Feb;109(2):111-113. doi: 10.1016/j.bulcan.2021.09.021. Epub 2022 Jan 5.
5
First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.一线帕博利珠单抗联合曲妥珠单抗治疗人表皮生长因子受体 2（HER2）阳性食管、胃或胃食管交界处癌：一项开放标签、单臂、2 期临床试验。
Lancet Oncol. 2020 Jun;21(6):821-831. doi: 10.1016/S1470-2045(20)30169-8. Epub 2020 May 18.
6
PD-L1 as a predictive biomarker for pembrolizumab in HER2-positive gastric or gastro-esophageal junction adenocarcinoma-a commentary on KEYNOTE-811.PD-L1作为帕博利珠单抗在HER2阳性胃或胃食管交界腺癌中的预测生物标志物——关于KEYNOTE-811的评论
Chin Clin Oncol. 2024 Aug;13(4):59. doi: 10.21037/cco-24-28. Epub 2024 Jun 6.
7
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.EORTC-1203-GITCG - “创新”试验：曲妥珠单抗单药与曲妥珠单抗加帕妥珠单抗联合化疗在 HER2 阳性胃和胃食管交界处腺癌围手术期治疗中的疗效对比：EORTC 胃肠道肿瘤研究组、韩国癌症研究组和荷兰上消化道肿瘤组的一项随机 II 期分组试验。
BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4.
8
[Pembrolizumab with trastuzumab and chemotherapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinomas with surexpression of HER2 and CPS≥1].帕博利珠单抗联合曲妥珠单抗及化疗用于HER2过表达且CPS≥1的晚期或转移性胃或胃食管交界腺癌
Bull Cancer. 2024 Feb;111(2):130-132. doi: 10.1016/j.bulcan.2023.11.004. Epub 2023 Dec 8.
9
Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma.帕博利珠单抗治疗晚期胃及胃食管结合部腺癌。
Future Oncol. 2018 Feb;14(5):417-430. doi: 10.2217/fon-2017-0436. Epub 2017 Nov 2.
10
Safety and efficacy of tislelizumab plus chemotherapy for first-line treatment of advanced esophageal squamous cell carcinoma and gastric/gastroesophageal junction adenocarcinoma.替雷利珠单抗联合化疗用于一线治疗晚期食管鳞状细胞癌和胃/胃食管交界腺癌的安全性和有效性。
Thorac Cancer. 2020 Dec;11(12):3419-3421. doi: 10.1111/1759-7714.13690. Epub 2020 Oct 12.